Clinical Trial Overview: Dapagliflozin for Heart Failure With Reduced Ejection Fraction
Study examines whether dapagliflozin is cost-effective when added to standard of care for patients who have heart failure with reduced ejection fraction.
An overview of the clinical trial titled, "Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction."
The study, published in JAMA, estimated the cost-effectiveness of dapagliflozin therapy among patients with chronic heart failure with reduced ejection fraction (HFrEF).
The study indicated that dapagliflozin is cost-effective for patients with HFrEF. As such, the study authors noted that the evidence of clinical benefit and economic value should be considered for increasing therapy rates among patients who have HFrEF with and without diabetes.